Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Cited by (279)

Items 101–200 of 279

1. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach
   Angelo DEL GAUDIO, Federica Di Vincenzo, Valentina Petito, Maria Cristina Giustiniani, Antonio Gasbarrini, Franco Scaldaferri, Loris Riccardo Lopetuso · 2023 · Inflammatory Bowel Diseases
2. Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series
   Anna Gil, George E. Hoag, John P. Salerno, Mady Hornig, Nancy G. Klimas, Liisa Kaarina Selin · 2023 · Brain Behavior & Immunity - Health
3. PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation – therapeutic implications for autoimmunity
   Yiqing Feng, Gordafaried Deyanat‐Yazdi, Kristin Newburn, Scott C. Potter, Mark A. Wortinger, Miriam Ramirez, Stephanie M.E. Truhlar, Pia P. Yachi · 2024 · Journal of Autoimmunity
4. Exosomal miR-125b-5p derived from mesenchymal stromal/stem cell enhances anti-PD-1 therapy in mouse colon cancer model
   Mengmeng Jiang, Jia Liu, Shengquan Hu, Xueqin Yan, Yongkai Cao, Zhengzhi Wu · 2025 · Stem Cell Research & Therapy
5. Immune checkpoint blockade for cancer therapy: current progress and perspectives
   Hongying Ye, Weijie Liao, Jiongli Pan, Yin Pu Shi, Qingqing Wang · 2025 · Journal of Zhejiang University SCIENCE B
6. Therapeutic Ultrasound-Enhanced Immune Checkpoint Inhibitor Therapy
   Jinyun Yuan, Dezhuang Ye, Si Chen, Hong Chen · 2021 · Frontiers in Physics
7. Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles
   Armita Mahdavi Gorabi, Mehrnaz Sadat Ravari, Mohammad‐Javad Sanaei, Soodabeh Davaran, Prashant Kesharwani, Amirhossein Sahebkar · 2022 · International Immunopharmacology
8. Update on Immune Checkpoint Inhibitor Enterocolitis
   Molly Rose Kelly‐Goss, Yousef R. Badran, Michael Lawrence Dougan · 2022 · Current Gastroenterology Reports
9. The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events
   Anqi Lin, Keyin Zheng, Aimin Jiang, Xufeng Huang, Qi Wang, András Hajdú, Zhengrui Li, Jian Zhang, Peng Luo · 2025 · Med Research
10. Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy
    Célia Jacoberger-Foissac, Stephen J. Blake, Jing Liu, Elizabeth McDonald, Hannah Triscott, Kyohei Nakamura, Mark John Smyth, Michele W.L. Teng · 2020 · Journal for ImmunoTherapy of Cancer
11. m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent
    Jianqiu Kong, Sihong Lu, Long Zhang, Yuhui Yao, Jie Zhang, Zefeng Shen, Mingli Luo, Bin Liu, Junjiong Zheng, Tianxin Lin · 2022 · Frontiers in Immunology
12. The Role of Programmed Death-1 in Type 1 Diabetes
    Christopher Tucker, Alexander J. Dwyer, Brian T. Fife, Tijana Martinov · 2021 · Current Diabetes Reports
13. Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
    Lulu Lv, Ruo han Huang, Jiale Li, Jing Xu, Wen Gao · 2022 · Biomarker Research
14. Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus
    Min Shen, Doudou Chen, Ruiling Zhao, Xuqin Zheng, Yong Gu, Tao Yang, Yun Shi · 2023 · Frontiers in Endocrinology
15. The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database
    Huaju Yang, Zheran Liu, Ruidan Li, Rendong Huang, Xingchen Peng · 2023 · Frontiers in Pharmacology
16. Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors
    Gregory E. Sanda, Julie M. Shabto, Subir Goyal, Yuan Liu, Dylan J. Martini, Bassel Nazha, Jacqueline Theresa Brown, Lauren Beth Yantorni, Greta Anne Russler, Sarah E. Caulfield et al. · 2023 · The Oncologist
17. Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions
    Michael Lawrence Dougan · 2023 · Immunological Reviews
18. Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma
    Lei Xu, Chao Leng, Lin Chen, Hanhua Dong, Yifa Chen, Xiaoping Chen · 2021 · International Journal of Cancer
19. Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas
    Jordan A. Stinson, Allison M. Sheen, Noor Momin, Jordan Hampel, Rebecca Bernstein, Rebecca L. Kamerer, Bahaa A. Fadl-Alla, Jonathan Samuelson, Elizabeth Fink, Timothy M. Fan et al. · 2023 · Clinical Cancer Research
20. Design of a potent interleukin-21 mimic for cancer immunotherapy
    Jung-Ho Chun, Birkley S. Lim, Suyasha Roy, Michael J. Walsh, Gita C. Abhiraman, Kevin Zhangxu, Tavus Atajanova, Or‐Yam Revach, Elisa C. Clark, Peng Li et al. · 2025 · Science Immunology
21. HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy
    Amanda Rosewell Shaw, Caroline E. Porter, Greyson W. G. Biegert, Lisa Jatta, Masataka Suzuki · 2022 · Cancers
22. Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon
    Beth Ann Helmink, Christina Lynn Roland, Colleen M. Kiernan, Jennifer Ann Wargo · 2020 · Annals of Surgical Oncology
23. Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis
    Reilly G. Fankhauser, Douglas Buckner Johnson, Javid J. Moslehi, Justin Micah Balko · 2025 · Nature Cardiovascular Research
24. STING pathway as a cancer immunotherapy: Progress and challenges in activating anti-tumor immunity
    Mohammad Mahdi Mokhtari Tabar, Mahnaz Fathi, Fatemeh Kazemi, Ghazal Bazregari, Abdolmajid Ghasemian · 2024 · Molecular Biology Reports
25. The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
    Tianhang Zhang, Haitao Lv, Jiasong Li, Shasha Zhang, Jingjing Zhang, Siqi Wang, Yingnan Wang, Zhanjun Guo · 2024 · Frontiers in Immunology
26. Stem-like T cells and niches: Implications in human health and disease
    Linglu Yi, Yang Li · 2022 · Frontiers in Immunology
27. Computational Design of an Allosteric Antibody Switch by Deletion and Rescue of a Complex Structural Constellation
    Jittasak Khowsathit, Andrea Bazzoli, Hong Cheng, John Karanicolas · 2020 · ACS Central Science
28. Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: Update on recent developments
    Jiaqi Li, Lin Chen, Xiaolin Liu, Mei Zhang, Xiaoling Liu · 2025 · Seminars in Cancer Biology
29. Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer
    Émeline Orillard, Arjab Adhikari, Reem Saleem Malouf, François Calais, Corynne Marchal, Virginie Westeel · 2024 · Cochrane Database of Systematic Reviews
30. A theranostic photosensitizer-conjugated albumin co-loading with resiquimod for cancer-targeted imaging and robust photo-immunotherapy
    Xu Tan, Yu Wang, Lei Long, Hongdan Chen, Langfan Qu, Xiaohui Cao, Huijuan Li, Zelin Chen, Shenglin Luo, Chunmeng Shi · 2024 · Pharmacological Research
31. Application of Immune Checkpoint Inhibitors in Cancer
    Zhijun Chen, Zihan Song, Shichen Den, Wei Zhang, Mengjia Han, Tianhang Lan, Xiaokang Du, J Ning, XinHui Chen, Haoming Lin et al. · 2025 · MedComm
32. Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis
    Wen Gao, Lingxiang Wu, Shidai Jin, Jun Li, Xinyin Liu, Jiali Xu, Wei Zhang, Qixing Gong, Chunxiao Sun, Wei Ting Wang et al. · 2022 · Journal for ImmunoTherapy of Cancer
33. Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors
    Qiuyu Wu, Yuanhang Xia, Xiaohe Xiong, Xinxing Duan, Xiaoxiao Pang, Fugui Zhang, Song Tang, Junlei Su, Shuqiong Wen, Li Mei et al. · 2023 · Frontiers in Pharmacology
34. Current landscape and tailored management of immune-related adverse events
    Wenhui Liu, Zhiying Luo, Yiping Liu, Bao Sun · 2023 · Frontiers in Pharmacology
35. PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
    Qingya Song, Zongliang Yu, Wenping Lü, Zhili Zhuo, Lei Chang, Heting Mei, Yongjia Cui, Dongni Zhang · 2025 · Human Vaccines & Immunotherapeutics
36. Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors
    Guilherme Ferreira de Britto Evangelista, Amanda Braga Figueiredo, Milton José de Barros e Silva, Kenneth J. Gollob · 2022 · Immunotherapy Advances
37. Nivolumab-associated active neutrophilic gastritis
    Laura Rovedatti, Marco Vincenzo Lenti, Alessandro Vanoli, Monica Feltri, Federico De Grazia, Antonio Di Sabatino · 2020 · Journal of Clinical Pathology
38. Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma
    Zhouhua Li, Wenjun Wang, Juan Wu, Xiaoqun Ye · 2022 · Frontiers in Medicine
39. Melanoma immunotherapy enabled by M2 macrophage targeted immunomodulatory cowpea mosaic virus
    Zhongchao Zhao, Young Hun Chung, Nicole F. Steinmetz · 2024 · Materials Advances
40. Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors
    Patrick Tiongco Magahis, Tara Corso, Pamela Livingstone, Erika Tom, Amitabh Srivastava, Michael Andrew Postow, David M. Faleck · 2024 · Journal for ImmunoTherapy of Cancer
41. A systematic review of gastritis as an immune-related adverse event in clinical interventions
    Fei Su, Wenxuan Fan, Yan Zhang, Xiaoling Zhang, Yunyi Du, Weiling Li, Wenqing Hu, Jun Zhao · 2024 · Human Vaccines & Immunotherapeutics
42. Detection of Patient-Level Immunotherapy-Related Adverse Events (irAEs) from Clinical Narratives of Electronic Health Records: A High-Sensitivity Artificial Intelligence Model
    Md Muntasir Zitu, Margaret Elena Gatti-Mays, Kai Johnson, Shijun Zhang, Aditi Shendre, Mohamed I. Elsaid, Lang Li · 2024 · Pragmatic and Observational Research
43. Systemic anti‐cancer therapy and anaesthesia: a narrative review
    Jamie M. J. Weaver, Susannah J. Patey · 2025 · Anaesthesia
44. PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease
    Juhi R. Kuchroo, Naomi Goldman, Arlene H. Sharpe · 2025 · Nature Reviews Rheumatology
45. Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy
    Sepehr Dadfar, Yasamin Eivazzadeh, Haniyeh Molavi, Hoda Abedi, Fatemeh Tavassoli Razavi, Dariush Haghmorad · 2026 · Inflammation Research
46. Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
    Marina A. Lyadova, Vladimir Konstantinovich Lyadov · 2021 · Journal of Modern Oncology
47. Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world
    Wen Hao, Wenjing Liu, Ruimin Chang, Mi Yang, Kai Xin, Jingxin Liu, Yibing Wang, Meijin Ren, Jiaqi Xie, Yang Yang · 2024 · Journal of Cancer Research and Clinical Oncology
48. Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
    Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi et al. · 2024 · Cancer Medicine
49. The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database
    Shun Li, Zhifei Huang, Xiaoyu Zhong, Yan Zhou, Hao Jiang · 2025 · BMC Cancer
50. PD‐1‐induced proliferating T cells exhibit a distinct transcriptional signature
    Marianne Strazza, Shoiab Bukhari, Anna S. Tocheva, Adam Mor · 2021 · Immunology
51. Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study
    Saara Kuusisalo, Jussi Pekka Koivunen, Sanna Iivanainen · 2022 · Cancers
52. Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-Analysis
    Joni Wahyuhadi, Irwan Barlian Immadoel Haq, Muhammad Reza Arifianto, Bagus Sulistyono, Rizki Meizikri, Atika Rosada, Cita Rosita Sigit Prakoeswa, Rahadian Indarto Susilo · 2022 · Cancer Control
53. Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis
    Alessandro Inno, Antonello Veccia, Giorgio Madonia, Alvise Berti, Roberto Bortolotti, Lorena Incorvaia, Antonio Dello Russo, Orazio Caffo, Stefania Gori · 2024 · Frontiers in Cardiovascular Medicine
54. Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
    Yuan Meng, Yingge Lv, Meng Shen, Wenwen Yu, Yumeng Liu, Ting Liu, Gen Liu, Shiya Ma, Zhenzhen Hui, Xiu-Bao Ren et al. · 2024 · Cancer Medicine
55. PET-based immunomapping of intratumoral CD4 + cells to monitor acquired resistance to checkpoint inhibitors
    Stefania Pezzana, Simone Blaess, Bjoern Traenkle, Anna Schaefer, Lara Ruoff, Bredi Tako, Salvador Castaneda Vega, Philipp D. Kaiser, Teresa R. Wagner, Irene González-Menéndez et al. · 2025 · Science Advances
56. Multi-faced roles of reactive oxygen species in anti-tumor T cell immune responses and combination immunotherapy
    Tao Wang, Haiyan Xu · 2022 · Exploration of Medicine
57. Elevated circulating memory T cells precede immunotherapy toxicities in melanoma
    Elisa Bello, Michael Lawrence Dougan · 2022 · Trends in cancer
58. Immune mediated colitis: a surgical perspective
    Khang Duy Ricky Le, Kay Tai Choy, Sara Roth, Alexander Graham Heriot, Joseph Cherng Huei Kong · 2023 · ANZ Journal of Surgery
59. Pneumonitis, appendicitis, and biliary obstruction during toripalimab treatment in a patient with extensive-stage small-cell lung cancer: a case report
    Yanli Qu, Zheng Wang, Jilong Feng, Lijun Wang, Hangyu Liu, Dan Liu, Yuxia Zhao, Ruoxi Yu, Wang Li, Deyu Sun et al. · 2021 · Annals of Palliative Medicine
60. Checking ovarian reserves after checkpoint blockade
    Stephanie A. Roberts, Michael Lawrence Dougan · 2022 · Nature Cancer
61. Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer
    Miso Park, Ji Won Kim · 2024 · Toxicological Research
62. Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer
    Michael Lawrence Dougan, Long H. Nguyen, Elizabeth L. Buchbinder, Hillard Michael Lazarus · 2024 · Cancers
63. Severe Dysphagia With Eosinophilic Esophagitis Pattern of Injury Related to Pembrolizumab Therapy
    James S. Barnett, Kevin K. Yu, Xavier Rivera Rivera, Asmeen Bhatt · 2024 · ACG Case Reports Journal
64. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity
    Shengsheng Mei, Shanshan Peng, Eu Gene Vong, Jin-biao Zhan · 2024 · International Immunopharmacology
65. In-depth cross-validation of human and mouse CD4-specific minibodies for noninvasive PET imaging of CD4+ cells and response prediction to cancer immunotherapy
    Stefania Pezzana, Simone Blaess, Jule Kortendieck, Nicole Hemmer, Bredi Tako, Claudia Pietura, Lara Ruoff, Simon Riel, Martin Schaller, Irene González-Menéndez et al. · 2024 · Theranostics
66. Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritis
    Elise F. Gray-Gaillard, Ami A. Shah, Clifton O. Bingham, Jennifer H. Elisseeff, Joseph Christopher Murray, Julie Renee Brahmer, Patrick M. Forde, Valsamo Anagnostou, Jennifer Sophie Mammen, Laura C. Cappelli · 2025 · Arthritis Research & Therapy
67. CanImmunother: a manually curated database for identification of cancer immunotherapies associating with biomarkers, targets, and clinical effects
    Wenliang Zhang, Binghui Zeng, Huancai Lin, Wen xian Guan, Jing Mo, Song Wu, Yanjie Wei, Qianshen Zhang, Dongsheng Yu, Weizhong Li et al. · 2021 · OncoImmunology
68. The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer
    Courtney H. Coschi, Rosalyn Anne Juergens · 2021 · Current Oncology
69. Transcriptome analysis of Homo sapiens and Mus musculus reveals mechanisms of CD8+ T cell exhaustion caused by different factors
    Lin Zhang, Hafumi Nishi · 2022 · PLoS ONE
70. PD-1 checkpoint blockade disrupts CD4 T cell regulated adaptive B cell tolerance to foreign antigens
    Chad R. Dufaud, Andrew G. Shuparski, Brett Higgins, Louise J. McHeyzer‐Williams, Michael G. McHeyzer‐Williams · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
71. Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment
    Lingpeng Tang, Dandan Wang, Ting Hu, Xiaoying Lin, Songsong Wu · 2024 · Cancer Drug Resistance
72. Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer
    Tae Kyun Kim, Hyun Seok Lee, Eun Soo Kim · 2024 · The Korean Journal of Internal Medicine
73. Checkpoint Molecules in Rheumatology—or the Benefits of Being Exhausted
    Stinne Ravn Greisen, Bent Winding Deleuran · 2021 · Current Rheumatology Reports
74. Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis
    You-Meng Sun, Wei Li, Zhiyu Chen, Ying Wang · 2021 · Frontiers in Oncology
75. Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma
    Yiran Lu, Qingchen Li, Lusi Xu, Ying Sun, Yanqing Zheng, Yanchao Wang, Ying Liu, Rui Zhang, Lin Liao, Jianjun Dong · 2023 · Journal of Cancer Research and Clinical Oncology
76. Testing Immune-Related Adverse Events in Cancer Immunotherapy
    Jocelyn R. Farmer · 2019 · Clinics in Laboratory Medicine
77. Stochastic Simulation on a Minimal Model of Cancer Immunoediting Theory
    M. Núñez‐López, Eymard Hernández–López, Joaquı́n Delgado · 2021 · International Journal of Bifurcation and Chaos
78. Biocatalysis of precursors to new-generation SB-T-taxanes effective against paclitaxel-resistant cancer cells
    Aimen Al‐Hilfi, Kevin D. Walker · 2022 · Archives of Biochemistry and Biophysics
79. Catch and release: freeing up PD-L1 ameliorates autoimmunity
    Stephanie Grebinoski, Angela Marie Gocher, Dario A.A. Vignali · 2022 · Nature Immunology
80. Immunotherapy-driven remodeling of the tumor immune microenvironment: Spatiotemporal heterogeneity and multidimensional dynamics
    Junjie Pan, Shixin Chen, Lingxiao Jin, Keye Chen, Zhaoming Ye, Binghao Li · 2026 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
81. Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research
    Raphael Yip, Gaston Arnolda, Klay Lamprell, Bróna Nic Giolla Easpaig, Renuka Chittajallu, Geoff P. Delaney, Ian Olver, Winston Liauw, Jeffrey Braithwaite · 2024 · Journal for ImmunoTherapy of Cancer
82. The Development of Persistent Gastrointestinal Symptoms in Patients With Melanoma Who Have Had an Immune Checkpoint Inhibitor-Related Gastrointestinal Toxicity
    Sanskriti Varma, Keri M. Sullivan, Jamie DiCarlo, Alexandra J. Coromilas, Kyle D. Staller, Michael Lawrence Dougan · 2024 · Clinical and Translational Gastroenterology
83. A historic cohort study of nutritional status related side effects and weight loss of cancer patients treated with immunotherapy
    D.M.K. Homan, P. Ruissen-Luijt, A. Boekhout, Jolanda M. Maaskant · 2021 · Clinical Nutrition ESPEN
84. Potent antitumor activity of a designed interleukin-21 mimic
    Jung-Ho Chun, Birkley S. Lim, Suyasha Roy, Michael J. Walsh, Gita C. Abhiraman, Kevin Zhangxu, Tavus Atajanova, Or‐Yam Revach, Elisa C. Clark, Peng Li et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
85. The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis
    Weixing Zhao, Bo Li, Yujia Gu, Xiaoni Jin, Zirui Li, Wanjing Guo, Xinxin Lü, Jun Jiang · 2025 · BMC Cancer
86. Safety of immune checkpoint inhibitors: A systematic review of disproportionality analysis studies
    Mahesh Rathod, Maheshwari Kadari, Anjana Das Kadavath, Christy Thomas, Anjali Raveendran K.V., Mahesh Jagtap, Krishna Undela · 2026 · European Journal of Clinical Pharmacology
87. Immune checkpoint inhibitor-induced gastrointestinal injury: prevalence of cytomegalovirus, adenovirus and Epstein-Barr virus
    Yevgen Chornenkyy, Carissa LaBoy, Sergei Xavier De Hoyos, Jingjing Hu, Maryam Kherad Pezhouh · 2024 · Journal of Clinical Pathology
88. Association Between Treatment-Related Adverse Event Trajectory and Prognosis in Esophageal Cancer Receiving Neoadjuvant Immunochemotherapy
    Zijie Li, Shujie Huang, Rixin Chen, Zhen Gao, Junhan Wu, Yizhang Chen, Weifeng Zhong, Sichao Wang, Guibin Qiao · 2024 · Annals of Surgical Oncology
89. Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment
    Xiaohu Zheng, Haiming Wei · 2021 · Frontiers in Oncology
90. Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice
    Shalom Lerrer, Adam Mor · 2019 · Translational Cancer Research
91. Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy
    Qianqian Hou, Heng Xu · 2020 · Advances in experimental medicine and biology
92. Drug-induced digestive tract injury: decoding some invisible offenders
    Dipti M. Karamchandani, Lindsey M. Westbrook, Christina A. Arnold · 2022 · Human Pathology
93. IMMUNE MODULATION OF CANCER: MECHANISMS AND RESISTANCE
    Lucia Lisi, Luigi Cari, Rosalinda Sorrentino, Enrico Mini, Carmela Fimognari, Giuseppe Nocentini · 2021
94. Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies
    Lei Zhang, Haitao Zhao · 2020 · HepatoBiliary Surgery and Nutrition
95. Immune Checkpoint Inhibitor Colitis: Resident Memory Unleashed
    Michael Lawrence Dougan · 2021 · Gastroenterology
96. Real-world analysis of immune checkpoint inhibitor efficacy and response predictors in patients treated at the CCCMunichLMU outpatient clinic
    Klara Dorman, Kilian Breitenwieser, Laura Elisabeth Fischer, Danmei Zhang, Victoria Probst, Lena Weiss, Kathrin Heinrich, Wolfgang Gerhard Kunz, Julian Walter Holch, Clemens Gießen-Jung et al. · 2025 · Scientific Reports
97. Management and Outcomes of Clostridioides difficile Infection in Patients on Immune Checkpoint Inhibitors
    Patrick Tiongco Magahis, Deepika Satish, Mini Kamboj, Ngolela Esther Babady, Jennele Baul, Hannah L. Kalvin, Katherine Panageas, Michael A. Postow, Monika Laszkowska, David M. Faleck · 2025 · Journal of the National Comprehensive Cancer Network
98. Multi-detector computed tomography (MDCT)–based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis
    Nisanard Pisuchpen, Sienna Durbin, Meghan J. Mooradian, Florian Johannes Fintelmann, Kerry Lynn Reynolds, Michael Lawrence Dougan, Avinash R. Kambadakone · 2021 · European Radiology
99. Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer
    Alexia François, Jean Descarpentrie, Iker Badiola, Géraldine Siegfried, Serge Évrard, Simon Pernot, Abdel‐Majid Khatib · 2022 · British Journal of Cancer
100. Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
     Sofía España, Chen Sun, Carme Solé-Blanch, Aram Boada, Anna Martínez‐Cardús, José Luís Manzano · 2023 · Pharmaceutics